We design, manufacture and sell a wearable cardioverter defibrillator for patients who are at higher risk of cardiac arrest. (Incorporated in Bermuda) 

We are commercializing our cardiac recovery system platform, an advanced comprehensive system that integrates monitoring, therapeutic treatment, digital health and patient support services into a single unified solution. Our ASSURE WCD is a next generation wearable cardioverter defibrillator (WCD) worn to protect patients who are at an elevated risk of sudden cardiac arrest.

Our ASSURE WCD has been worn by more than 17,000 patients since it was commercially launched in August 2022. Our cardiac recovery system – as of Jan. 31, 2025 – is actively prescribed by more than 550 U.S. hospitals.

Note: Net loss and revenue are for the 12 months that ended Oct. 31, 2024. 

(Note: Kestra Medical Technologies, Ltd. priced its upsized IPO at $17.00 – $1.00 above the top of its $14.00-to-$16.00 range – and sold 11.88 million shares (11,882,352 shares) – up from 10.0 million shares in the prospectus – to raise about $202 million on Wednesday night, March 5, 2025.)

(Note: Kestra Medical Technologies, Ltd., disclosed its IPO’s terms in an S-1/A filing dated Feb. 26, 2025: The company is offering 10.0 million shares at a price range of $14.00 to $16.00 to raise $150.0 million, if priced at the $15.00 mid-point of its range. Background: Kestra Medical Technologies, Ltd. filed its S-1 on Feb. 10, 2025, for its IPO, which was expected to raise at least $100 million, a placeholder figure.The company submitted confidential IPO documents to the SEC on Aug. 25, 2021.)